Nyxoah (NASDAQ:NYXH) vs. IceCure Medical (NASDAQ:ICCM) Financial Review

IceCure Medical (NASDAQ:ICCM) and Nyxoah (NASDAQ:NYXH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent recommendations for IceCure Medical and Nyxoah, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	2	0	3	0	2.20
Nyxoah	1	1	2	0	2.25

IceCure Medical presently has a consensus price target of $52.50, indicating a potential upside of 2,223.01%. Nyxoah has a consensus price target of $4.26, indicating a potential upside of 182.25%. Given IceCure Medical’s higher probable upside, equities analysts plainly believe IceCure Medical is more favorable than Nyxoah.

Volatility and Risk

IceCure Medical has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.

Earnings & Valuation

This table compares IceCure Medical and Nyxoah”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.95 million	1.96	-$15.06 million	($8.52)	-0.27
Nyxoah	$21.66 million	2.70	-$101.92 million	($2.52)	-0.60

IceCure Medical has higher earnings, but lower revenue than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

0.6% of IceCure Medical shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 17.1% of Nyxoah shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares IceCure Medical and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
Nyxoah	-443.16%	-178.90%	-81.83%

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.